Similares a SUNRISE: Tezepelumab Shows Meaningful OCS Reduction in Severe Asthma

20 vecinos (text_768) · 78 views · HCPLive · Estados Unidos


★	SUNRISE: Tezepelumab Shows Meaningful OCS Reduction in Severe Asthma	HCPLive @hcplivenews	78	Estados Unidos
5	Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients \| ATS 2026	HCPLive @hcplivenews	1.2K	Estados Unidos	86
10	Precision Mold Detoxification with Beth O'Hara, Functional Naturopath	Hawthorn University @hawthornuniversity	587	—	84
11	Potential Biomarker to Identify Pregnant Women at Greater Risk for #Asthma Exacerbations I ATS 2026	HCPLive @hcplivenews	453	Estados Unidos	84
14	Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD	HCPLive @hcplivenews	198	Estados Unidos	84
6	AD109 Shows Promise as Oral Agent for Obstructive Sleep Apnea, With Patrick John Strollo, MD	HCPLive @hcplivenews	129	Estados Unidos	86
2	Tezepelumab Reduced Severe Asthma Exacerbations Across Phenotypes \| ATS 2026	HCPLive @hcplivenews	122	Estados Unidos	90
4	Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease \| ATS 2026 With Gerard Criner, MD	HCPLive @hcplivenews	113	Estados Unidos	86
7	AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD	HCPLive @hcplivenews	105	Estados Unidos	85
15	What Does New Phase 3 Amlitelimab Data Suggest for Atopic Dermatitis?	HCPLive @hcplivenews	92	Estados Unidos	84
20	What Is Next for OX40 Ligand Inhibition in Atopic Dermatitis?	HCPLive @hcplivenews	91	Estados Unidos	84
13	Phase 3b Data on Ixekizumab, Tirzepatide for Psoriasis and Overweight, With Mark Lebwohl, MD	HCPLive @hcplivenews	88	Estados Unidos	84
9	Dupilumab Doubled Asthma Remission Odds in Type 2 Asthma:	HCPLive @hcplivenews	71	Estados Unidos	85
1	ATS 2026 Asthma Updates: Tezepelumab, Dupilumab, OCS Reduction & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	70	Estados Unidos	91
3	Tezepelumab Cuts Severe Asthma Exacerbations 70% in Real-World Patients \| ATS 2026	HCPLive @hcplivenews	68	Estados Unidos	90
18	Omalizumab vs Oral Immunotherapy for Multifood Allergy	HCPLive @hcplivenews	65	Estados Unidos	84
16	Can CSU Patients Achieve True Remission? BTK Inhibitors, Biomarker Barriers, & More \| EAC 2026	HCPLive @hcplivenews	58	Estados Unidos	84
8	ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	55	Estados Unidos	85
19	Respiratory Disorder Drug Therapy \| Chapter 27 – Brenner & Stevens’ Pharmacology (6th)	Last Minute Lecture @lastminutelecture	52	Estados Unidos	84
12	Biologic Selection in Severe Asthma: Biomarkers, Comorbidities & Switching Strategies	HCPLive @hcplivenews	36	Estados Unidos	84
17	Discussing Zumilokibart Data in Atopic Dermatitis, With Ruth Ann Vleugels, MD, MPH, MBA	HCPLive @hcplivenews	30	Estados Unidos	84